[1]
Bertoluci M, Rocha V. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr 2017; 9: 25.
[http://dx.doi.org/10.1186/s13098-017-0225-1]
[http://dx.doi.org/10.1186/s13098-017-0225-1]
[2]
Mansour AA, Douri FA. Diabetes in Iraq: Facing the epidemic. A systematic Review. Wulfernia 2015; 22(3): 258-73.
[3]
Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010; 170: 27-40.
[http://dx.doi.org/10.1001/archinternmed.2009.434] [PMID: 20065196]
[http://dx.doi.org/10.1001/archinternmed.2009.434] [PMID: 20065196]
[4]
Kyriakos G, Quiles-Sanchez LV, Garmpi, et al. Cardiovascular and renal outcomes of incretin-based therapies: A review of recent clinical trials. Curr Cardiol Rev 2020; 16(4): 253-7.
[http://dx.doi.org/10.2174/1573403X15666190603111056] [PMID: 31161994]
[http://dx.doi.org/10.2174/1573403X15666190603111056] [PMID: 31161994]
[5]
Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9(7): 551-9.
[http://dx.doi.org/10.1038/nrd3180 ] [PMID: 20508640]
[http://dx.doi.org/10.1038/nrd3180 ] [PMID: 20508640]
[6]
Kyriakos G, Quiles-Sanchez LV, Garmpi A, et al. SGLT2 inhibitors and cardiovascular outcomes: Do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study. Curr Cardiol Rev 2020; 16(4): 258-65.
[http://dx.doi.org/10.2174/1573403X15666190730094215] [PMID: 31362691]
[http://dx.doi.org/10.2174/1573403X15666190730094215] [PMID: 31362691]
[7]
Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble JM. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis. Am J Kidney Dis 2016; 68(5): 733-42.
[http://dx.doi.org/10.1053/j.ajkd.2016.06.014] [PMID: 27528374]
[http://dx.doi.org/10.1053/j.ajkd.2016.06.014] [PMID: 27528374]
[8]
Damaskos C, Garmpis N, Kollia P, et al. Assessing cardiovascular risk in patients with diabetes: An update. Curr Cardiol Rev 2020; 16(4): 266-74.
[http://dx.doi.org/10.2174/1573403X15666191111123622] [PMID: 31713488]
[http://dx.doi.org/10.2174/1573403X15666191111123622] [PMID: 31713488]
[9]
Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? An overview. Saudi J Gastroenterol 2016; 22(2): 91-105.
[PMID: 26997214]
[PMID: 26997214]
[10]
Damaskos C, Litos A, Dimitroulis D, et al. Cardiovascular effects of metabolic surgery on type 2 diabetes. Curr Cardiol Rev 2020; 16(4): 275-84.
[http://dx.doi.org/10.2174/1573403X16666200220120226] [PMID: 32077829]
[http://dx.doi.org/10.2174/1573403X16666200220120226] [PMID: 32077829]
[11]
Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study. Obesity (Silver Spring) 2014; 22(1): 5-13.
[http://dx.doi.org/10.1002/oby.20662 ] [PMID: 24307184]
[http://dx.doi.org/10.1002/oby.20662 ] [PMID: 24307184]
Article Metrics
4